Side-by-side comparison of AI visibility scores, market position, and capabilities
Vienna Austria YC W21 desktop DNA synthesizer enabling on-demand oligo production in research labs at $3.1M revenue 2024; $1.99M BioTools Innovator-backed "Nespresso for DNA" at $35.5-49.5K competing with IDT and Evonetix for benchtop DNA synthesis.
Kilobaser is a Vienna, Austria-based biotechnology hardware company — backed by Y Combinator (W21) with $1.99 million in total funding from BioTools Innovator — providing research laboratories and life sciences companies with desktop DNA and RNA oligonucleotide synthesizers that enable individual scientists to produce custom synthetic DNA sequences directly on their benchtops without sending samples to commercial synthesis services, generating $3.1 million in annual revenue in 2024 with consistent revenue growth since the 2014 company founding. Positioned as the "Nespresso Machine for DNA," Kilobaser offers the Basic Edition synthesizer ($35,500) and Extended Edition ($49,500) — compact, affordable instruments that democratize access to on-demand DNA synthesis for research labs that need rapid turnaround on custom oligonucleotide sequences for PCR primers, CRISPR guides, sequencing adapters, and synthetic gene construction.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.